相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。FGF19 amplification reveals an oncogenic dependency upon autocrine FGF19/FGFR4 signaling in head and neck squamous cell carcinoma
Lixia Gao et al.
ONCOGENE (2019)
Implications of FGF19 on sorafenib-mediated nitric oxide production in hepatocellular carcinoma cells - a short report
Lixia Gao et al.
CELLULAR ONCOLOGY (2018)
Forkhead box Cl promotes colorectal cancer metastasis through transactivating ITGA7 and FGFR4 expression
Jian Liu et al.
ONCOGENE (2018)
FGFR4 provides the conduit to facilitate FGF19 signaling in breast cancer progression
Xiangdong Zhao et al.
MOLECULAR CARCINOGENESIS (2018)
Making way for suppressing the FGF19/FGFR4 axis in cancer
Nestor Prieto-Dominguez et al.
FUTURE MEDICINAL CHEMISTRY (2018)
A New Method to Study Heterodimerization of Membrane Proteins and Its Application to Fibroblast Growth Factor Receptors
Nuala Del Piccolo et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2017)
FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib
Lixia Gao et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2017)
FGF19 genetic amplification as a potential therapeutic target in lung squamous cell carcinomas
Xiaochen Zhang et al.
THORACIC CANCER (2017)
H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma
Jaya Julie Joshi et al.
CANCER RESEARCH (2017)
Ph I/II study of FGF401 in adult pts with HCC or solid tumors characterized by FGFR4/KLB expression
Stephen L. Chan et al.
CANCER RESEARCH (2017)
FGFR a promising druggable target in cancer: Molecular biology and new drugs
Rut Porta et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2017)
Advances and challenges in targeting FGFR signalling in cancer
Irina S. Babina et al.
NATURE REVIEWS CANCER (2017)
AKT/PKB Signaling: Navigating the Network
Brendan D. Manning et al.
CELL (2017)
The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing
Teresa Helsten et al.
CLINICAL CANCER RESEARCH (2016)
Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23
Chiara Degirolamo et al.
NATURE REVIEWS DRUG DISCOVERY (2016)
FGF19 promotes epithelial-mesenchymal transition in hepatocellular carcinoma cells by modulating the GSK3β/β-catenin signaling cascade via FGFR4 activation
Huakan Zhao et al.
ONCOTARGET (2016)
U3-1784, a human anti-FGFR4 antibody for the treatment of cancer
Rene Bartz et al.
CANCER RESEARCH (2016)
First-in-human study of BLU-554, a potent, highly-selective FGFR4 inhibitor designed for hepatocellular carcinoma (HCC) with FGFR4 pathway activation
R. Kim et al.
EUROPEAN JOURNAL OF CANCER (2016)
Stapled peptides: providing the best of both worlds in drug development
Xiayang Xie et al.
FUTURE MEDICINAL CHEMISTRY (2016)
Fibroblast growth factor receptor 4 (FGFR4) and fibroblast growth factor 19 (FGF19) autocrine enhance breast cancer cells survival
Kai Hung Tiong et al.
ONCOTARGET (2016)
Up-regulation of fibroblast growth factor 19 and its receptor associates with progression from fatty liver to hepatocellular carcinoma
Yan Li et al.
ONCOTARGET (2016)
A Phase 2 Trial of Lenvatinib (E7080) in Advanced, Progressive, Radioiodine-Refractory, Differentiated Thyroid Cancer: A Clinical Outcomes and Biomarker Assessment
Maria E. Cabanillas et al.
CANCER (2015)
Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications
Teresa Helsten et al.
CANCER AND METASTASIS REVIEWS (2015)
Targeting FGFR Signaling in Cancer
Mehdi Touat et al.
CLINICAL CANCER RESEARCH (2015)
Targeting FGF19 Binding to Its Receptor System: A Novel Therapeutic Approach for Hepatocellular Carcinoma
Nadia Panera et al.
HEPATOLOGY (2015)
Fibroblast Growth Factor Receptor 3 Isoforms: Novel Therapeutic Targets for Hepatocellular Carcinoma?
Jakob Paur et al.
HEPATOLOGY (2015)
Quantitative Proteomic Verification of Membrane Proteins as Potential Therapeutic Targets Located in the 11q13 Amplicon in Cancers
Heather Hoover et al.
JOURNAL OF PROTEOME RESEARCH (2015)
Fibroblast growth factor 19 is correlated with an unfavorable prognosis and promotes progression by activating fibroblast growth factor receptor 4 in advanced-stage serous ovarian cancer
Lingling Hu et al.
ONCOLOGY REPORTS (2015)
FGFR4 Is a Potential Predictive Biomarker in Oral and Oropharyngeal Squamous Cell Carcinoma
Koos Koole et al.
PATHOBIOLOGY (2015)
Frequent methylation of the KLOTHO gene and overexpression of the FGFR4 receptor in invasive ductal carcinoma of the breast
Ashraf Dallol et al.
TUMOR BIOLOGY (2015)
First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway
Margit Hagel et al.
CANCER DISCOVERY (2015)
Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors
R. Dienstmann et al.
ANNALS OF ONCOLOGY (2014)
A phase I trial of LY2874455, a fibroblast growth factor receptor inhibitor, in patients with advanced cance
Jeanne Tie et al.
CANCER RESEARCH (2014)
Is Fibroblast Growth Factor Receptor 4 a Suitable Target of Cancer Therapy?
Christine Heinzle et al.
CURRENT PHARMACEUTICAL DESIGN (2014)
Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors
Li Tan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Fibroblast growth factor receptor 4 (FGFR4): a targetable regulator of drug resistance in colorectal cancer
R. C. Turkington et al.
CELL DEATH & DISEASE (2014)
Long-term exposure to sorafenib of liver cancer cells induces resistance with epithelial-to-mesenchymal transition, increased invasion and risk of rebound growth
Hannah van Malenstein et al.
CANCER LETTERS (2013)
FGFR4 Role in Epithelial-Mesenchymal Transition and Its Therapeutic Value in Colorectal Cancer
Alberto Pelaez-Garcia et al.
PLOS ONE (2013)
Targeting Wild-Type and Mutationally Activated FGFR4 in Rhabdomyosarcoma with the Inhibitor Ponatinib (AP24534)
Samuel Q. Li et al.
PLOS ONE (2013)
Fibroblast Growth Factor Receptor Inhibitors as a Cancer Treatment: From a Biologic Rationale to Medical Perspectives
Maria Vittoria Dieci et al.
CANCER DISCOVERY (2013)
Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma
Seiki Miura et al.
BMC CANCER (2012)
A phase I dose escalation study of NVP-BGJ398, a selective pan FGFR inhibitor in genetically preselected advanced solid tumors
Jurgen Wolf et al.
CANCER RESEARCH (2012)
AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family
Paul R. Gavine et al.
CANCER RESEARCH (2012)
Second-Line Therapies in Hepatocellular Carcinoma: Emergence of Resistance to Sorafenib
Augusto Villanueva et al.
CLINICAL CANCER RESEARCH (2012)
NADPH oxidase-dependent oxidative stress in the failing heart: From pathogenic roles to therapeutic approach
Yanti Octavia et al.
FREE RADICAL BIOLOGY AND MEDICINE (2012)
Identification of a Therapeutic Strategy Targeting Amplified FGF19 in Liver Cancer by Oncogenomic Screening
Eric T. Sawey et al.
CANCER CELL (2011)
Tumor Metastasis: Molecular Insights and Evolving Paradigms
Scott Valastyan et al.
CELL (2011)
FGF19 Regulates Cell Proliferation, Glucose and Bile Acid Metabolism via FGFR4-Dependent and Independent Pathways
Ai-Luen Wu et al.
PLOS ONE (2011)
FGF19 as a Postprandial, Insulin-Independent Activator of Hepatic Protein and Glycogen Synthesis
Serkan Kir et al.
SCIENCE (2011)
The FGFR4 Y367C mutant is a dominant oncogene in MDA-MB453 breast cancer cells
A. Roidl et al.
ONCOGENE (2010)
Resistance to Chemotherapy Is Associated with Fibroblast Growth Factor Receptor 4 Up-Regulation
Andreas Roidl et al.
CLINICAL CANCER RESEARCH (2009)
Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention
Han Kiat Ho et al.
JOURNAL OF HEPATOLOGY (2009)
FGFR4 prevents hyperlipidemia and insulin resistance but underlies high-fat diet-induced fatty liver
Xinqiang Huang et al.
DIABETES (2007)
Liver-specific activities of FGF19 require Klotho beta
Benjamin C. Lin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Receptor specificity of the fibroblast growth factor family - The complete mammalian FGF family
Xiuqin Zhang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Embryonic myogenesis pathways in muscle regeneration
P Zhao et al.
DEVELOPMENTAL DYNAMICS (2004)
Increased carbon tetrachloride-induced liver injury and fibrosis in FGFR4-deficient mice
CD Yu et al.
AMERICAN JOURNAL OF PATHOLOGY (2002)
FGFR4 overexpression in pancreatic cancer is mediated by an intronic enhancer activated by HNF1α
RNH Shah et al.
ONCOGENE (2002)
High-resolution mapping of the 11q13 amplicon and identification of a gene, TAOS1, that is amplified and overexpressed in oral cancer cells
X Huang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
分享论文
